A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma Meeting Abstract
| Authors: | Harding, J.; Ikeda, M.; Goyal, L.; Rodon, J.; Bai, L.; Oh, D.; Park, J.; Chen, L.; Ueno, M.; Liao, C.; Kondo, S.; Cosman, R.; Yokota, T.; Shroff, R.; Satoh, T.; Palmieri, L.; Hollebecque, A.; Adeva, J.; Bender, M.; Liu, H.; Macarulla, T. |
| Abstract Title: | A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma |
| Meeting Title: | 25th World Congress on Gastrointestinal Cancer (ESMO 2023) |
| Keywords: | oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Jun 28-Jul 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-06-01 |
| Start Page: | S161 |
| Language: | English |
| ACCESSION: | WOS:001037960400425 |
| DOI: | 10.1016/j.annonc.2023.04.473 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: S0-1 -- Source: Wos |
